{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:33:02Z","timestamp":1790415182011,"version":"4.1.0"},"reference-count":26,"publisher":"Jaypee Brothers Medical Publishing","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.59556\/japi.74.1295","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:09:56Z","timestamp":1771823396000},"page":"19-21","source":"Crossref","is-referenced-by-count":1,"title":["The Pharmacological Properties and Safety Profile of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction"],"prefix":"10.59556","volume":"74","author":[{"given":"Dharmesh","family":"Solanki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Badani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangesh","family":"Tiwaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PK","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PK","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Ganesh","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Febin","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarnath","family":"Sugumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthilnathan","family":"Mohanasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"key":"key20260223054901_B1","doi-asserted-by":"crossref","first-page":"78\u2013","DOI":"10.1016\/j.coph.2016.02.005","article-title":"Mineralocorticoid receptor antagonists \u2014 pharmacodynamics and pharmacokinetic differences.","volume":"27:","author":"Yang","year":"2016;","journal-title":"Curr Opin Pharmacol"},{"issue":"(16):","key":"key20260223054901_B2","doi-asserted-by":"crossref","first-page":"9088.","DOI":"10.3390\/ijms25169088","article-title":"Clinical properties and non-clinical testing of mineralocorticoid receptor antagonists in in vitro cell models.","volume":"25","author":"Varda","year":"2024;","journal-title":"Int J Mol Sci"},{"key":"key20260223054901_B3","unstructured":"Patibandla S, Heaton J, Kyaw H. Spironolactone. In: StatPearls. StatPearls Publishing; 2025. Accessed April 24, 2025. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554421\/"},{"issue":"(2):","key":"key20260223054901_B4","doi-asserted-by":"crossref","first-page":"169\u2013","DOI":"10.1007\/s40257-016-0245-x","article-title":"Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review.","volume":"18","author":"Layton","year":"2017;","journal-title":"Am J Clin Dermatol"},{"key":"key20260223054901_B5","unstructured":"Hughes JC, Cassagnol M. Eplerenone. In: StatPearls. StatPearls Publishing; 2025. Accessed April 23, 2025. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553100\/"},{"issue":"(5):","key":"key20260223054901_B6","doi-asserted-by":"crossref","first-page":"1680\u2013","DOI":"10.1016\/0016-5085(92)91730-R","article-title":"Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites.","volume":"102","author":"Sungaila","year":"1992;","journal-title":"Gastroenterology"},{"issue":"(8):","key":"key20260223054901_B7","doi-asserted-by":"crossref","first-page":"1451\u2013","DOI":"10.1002\/ejhf.1802","article-title":"Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.","volume":"22","author":"de Denus","year":"2020;","journal-title":"Eur J Heart Fail"},{"key":"key20260223054901_B8","unstructured":"ALDACTONE\u00ae (spironolactone) Prescribing Information. Accessed April 23, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/012151s075lbl.pdf"},{"key":"key20260223054901_B9","unstructured":"PubChem. Spironolactone. Accessed April 23, 2025. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/5833"},{"issue":"(5):","key":"key20260223054901_B10","doi-asserted-by":"crossref","first-page":"531\u2013","DOI":"10.1038\/clpt.1986.219","article-title":"Influence of food on the bioavailability of spironolactone.","volume":"40","author":"Overdiek","year":"1986;","journal-title":"Clin Pharmacol Ther"},{"issue":"(11):","key":"key20260223054901_B11","doi-asserted-by":"crossref","first-page":"1762\u2013","DOI":"10.1345\/aph.1P338","article-title":"Spironolactone management of resistant hypertension.","volume":"44","author":"Marrs","year":"2010;","journal-title":"Ann Pharmacother"},{"issue":"(1):","key":"key20260223054901_B12","first-page":"73\u2013","article-title":"A literature review of the pharmacokinetics, pharmacodynamics, and possible uses of spironolactone.","volume":"2","author":"Khan","year":"2021;","journal-title":"UTSC J Nat Sci"},{"key":"key20260223054901_B13","unstructured":"INSPRA\u00ae (eplerenone) Prescribing Information. Accessed April 23, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021437s013lbl.pdf"},{"key":"key20260223054901_B14","doi-asserted-by":"crossref","first-page":"9\u2013","DOI":"10.1016\/j.toxlet.2019.08.003","article-title":"The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism.","volume":"315:","author":"McGraw","year":"2019;","journal-title":"Toxicol Lett"},{"issue":"(3):","key":"key20260223054901_B15","doi-asserted-by":"crossref","first-page":"623.","DOI":"10.3390\/plants12030623","article-title":"Potential pharmacokinetic interactions of common cardiovascular drugs and selected European and Latin American Herbal Medicines: a scoping review.","volume":"12","author":"Prieto-Garcia","year":"2023;","journal-title":"Plants"},{"key":"key20260223054901_B16","unstructured":"Eplerenone - an overview | ScienceDirect Topics. Accessed April 23, 2025. https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/eplerenone"},{"key":"key20260223054901_B17","article-title":"Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment | Request PDF.","journal-title":"ResearchGate."},{"issue":"(10):","key":"key20260223054901_B18","doi-asserted-by":"crossref","first-page":"1984\u2013","DOI":"10.1093\/ndt\/gfg339","article-title":"Aldosterone receptor blockade and the role of eplerenone: evolving perspectives.","volume":"18","author":"Epstein","year":"2003;","journal-title":"Nephrol Dial Transplant"},{"issue":"(1):","key":"key20260223054901_B19","doi-asserted-by":"crossref","first-page":"1.","DOI":"10.4103\/ed.ed_7_21","article-title":"Eplerenone\u2013a novel mineralocorticoid receptor antagonist for the clinical application.","volume":"7","author":"Wu","year":"2022;","journal-title":"Environ Dis"},{"issue":"(14):","key":"key20260223054901_B20","doi-asserted-by":"crossref","first-page":"1309\u2013","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003;","journal-title":"N Engl J Med"},{"issue":"(3):","key":"key20260223054901_B21","doi-asserted-by":"crossref","first-page":"169\u2013","DOI":"10.1111\/j.1527-3466.2003.tb00114.x","article-title":"Eplerenone: a selective aldosterone blocker.","volume":"21","author":"Stier","year":"2003;","journal-title":"Cardiovasc Drug Rev"},{"issue":"(8):","key":"key20260223054901_B22","first-page":"122\u2013","article-title":"Gynecomastia and antihypertensive therapy.","volume":"6","author":"Mosenkis","year":"2007;","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"key20260223054901_B23","doi-asserted-by":"crossref","first-page":"100770.","DOI":"10.1016\/j.preteyeres.2019.07.003","article-title":"Central serous chorioretinopathy: towards an evidence-based treatment guideline.","volume":"73:","author":"van Rijssen","year":"2019;","journal-title":"Prog Retin Eye Res"},{"issue":"(Suppl 1):","key":"key20260223054901_B24","doi-asserted-by":"crossref","first-page":"ehz748.0065.","DOI":"10.1093\/eurheartj\/ehz748.0065","article-title":"1418 Adverse effects of spironolactone in long-term treatment of resistant arterial hypertension.","volume":"40","author":"Vaclavik","year":"2019;","journal-title":"Eur Heart J"},{"issue":"(15):","key":"key20260223054901_B25","doi-asserted-by":"crossref","first-page":"1383\u2013","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction.","volume":"370","author":"Pitt","year":"2014;","journal-title":"N Engl J Med"},{"key":"key20260223054901_B26","doi-asserted-by":"crossref","first-page":"25\u2013","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone.","volume":"200:","author":"Lainscak","year":"2015;","journal-title":"Int J Cardiol"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:49:10Z","timestamp":1771825750000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-1-s1-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.59556\/japi.74.1295"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1295","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}